top of page
  • Writer's pictureHannah Hunt

Introducing: The Lumella® bedside test for Pre-eclampsia

Preeclampsia is a well known condition, affecting around 6% of all pregnancies. It is typically characterised by proteinuria and high blood pressure, but some with the condition have no symptoms and progression can be unpredictable. It can pose significant risks to both the mother and the baby if left untreated, with many currently available tests requiring blood draws and lengthy lab analysis.

Lumella is a new point-of-care risk assessment tool, with digital results in 10 minutes using only a single drop of blood. Multiple hospitals are scheduled to trial Lumella in the UK this year.

Introducing Lumella

Lumella represents a significant development in PE testing, offering a non-invasive and accurate method for preeclampsia screening. Lumella uses the novel biomarker, GlyFN, demonstrating excellent outcomes when compared with other available biomarker tests, including PlGF, with a specificity of 92.8% and sensitivity of 98.5% 1. GlyFN levels are significantly elevated even as early as the first trimester in patients with preeclampsia.

How Lumella Works

The Lumella test can be taken and analysed entirely by bedside. Using a handheld digital reader included in the test kit, the simple 4-step process generates a ‘normal’ ‘positive’ or ‘high positive’ result in just 10 minutes. A high positive result indicates there is a high risk of delivery within 14 days, as well as other severe complications such as HELPP syndrome. 

The Benefits of Lumella

  • High accuracy when compared to other available tests

  • Quick and simple 4-step testing procedure

  • No specialised lab equipment, centrifugation, or cold storage required

  • Cost and time effective - reduces unnecessary admissions

  • Minimally invasive - only a single drop of blood required

  • All necessary equipment - such as lancet, swab, reader, and cartridges - are included in the kit

Supported by an ever-growing library of evidence

Click to read the studies

Click here to learn more or book a meeting with a Lumella expert.

Text and figures references:

  1. BJOG Glycosylated fibronectin point-of-care test for diagnosis of preeclampsia in a low-resource setting: a prospective Southeast Asia population study- 2020.10.1111/1471-0528.16323

  2. Rasanen et al. Maternal serum glycosylated fibronectin as a point-of care biomarker for assessment of preeclampsia. American Journal of Obstetrics and Gynecology 2015:212:82.e1-9

  3. Craig Saffer, Gayle Olson, Kim A. Boggess, Richard Beyerlein, Charles Eubank, Baha M. Sibai. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia, Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health. Volume 3, Issue 2, 2013. Pages 124-132. ISSN 2210-7789

39 views0 comments


bottom of page